Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.33) by 14.37 percent. This is a 28.21 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $3.941 million which beat the analyst consensus estimate of $2.610 million by 51.00 percent. This is a 89.74 percent increase over sales of $2.077 million the same period last year.